120 related articles for article (PubMed ID: 38888921)
1. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
[TBL] [Abstract][Full Text] [Related]
2. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
[TBL] [Abstract][Full Text] [Related]
3. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
4. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
5. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
6. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
7. Predictors of availability of long-acting medication for opioid use disorder.
Shover CL; Humphreys K
Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
[TBL] [Abstract][Full Text] [Related]
8. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder.
Alinsky RH; Hadland SE; Matson PA; Cerda M; Saloner B
J Adolesc Health; 2020 Oct; 67(4):542-549. PubMed ID: 32336560
[TBL] [Abstract][Full Text] [Related]
9. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
10. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
11. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
12. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
13. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
14. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
15. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States.
Paschen-Wolff MM; Velasquez R; Aydinoglo N; Campbell ANC
J Subst Abuse Treat; 2022 Sep; 140():108828. PubMed ID: 35749919
[TBL] [Abstract][Full Text] [Related]
16. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
Krawczyk N; Garrett B; Ahmad NJ; Patel E; Solomon K; Stuart EA; Saloner B
Drug Alcohol Depend; 2021 Mar; 220():108512. PubMed ID: 33508692
[TBL] [Abstract][Full Text] [Related]
17. Availability of Specific Programs and Medications for Addiction Treatment to Vulnerable Populations: Results from the Addiction Treatment Locator, Assessment, and Standards (ATLAS) Survey.
Oldfield BJ; Chen K; Joudrey PJ; Biegacki ET; Fiellin DA
J Addict Med; 2023 Jul-Aug 01; 17(4):477-480. PubMed ID: 37579115
[TBL] [Abstract][Full Text] [Related]
18. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
20. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]